Your Genome Is a Corporate Forecasting Tool, Not Just Your Privacy
Genetic testing framed as a wellness incentive actually functions as a corporate actuarial mechanism, exposing a structural gap in employment law.
A 2018 EEOC settlement against Orion Energy Systems revealed how genetic screenings tied to workplace wellness penalties serve corporate forecasting rather than individual health. While GINA blocks overt discrimination, it fails to prevent employers from aggregating polygenic risk scores to predict workforce healthcare liabilities. Until employment law treats sequenced genomes as inalienable rather than contractually waivable, voluntary workplace consent will continue operating as a proxy for corporate risk management.
In 2018, the EEOC settled an enforcement action against Orion Energy Systems after the company tied a $500 monthly wellness penalty to employees’ refusal to complete voluntary genetic screenings. The settlement resolved a narrow statutory question about consent, but it exposed a wider structural gap. HR departments are rarely screening for current employee health. They are pricing the future insurability of employees’ children. The Genetic Information Nondiscrimination Act was drafted to block overt discrimination in hiring and insurance underwriting. It does not prevent employers from aggregating polygenic risk scores across a workforce to forecast long-term healthcare liabilities. When genetic testing is framed as a wellness incentive, the legal architecture treats it as an individual privacy choice. In practice, it functions as a corporate forecasting mechanism. Treating heritable genetic data as a privacy boundary misses its actual function as an unpriced corporate actuarial asset. Until employment law treats sequenced genomes as inalienable rather than contractually waivable, workplace consent will continue to operate as a proxy for corporate risk management. The immediate compliance task is to map where voluntary disclosure ends and actuarial forecasting begins.